Published in Blood on September 01, 1985
AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol (1991) 1.45
Different Epstein-Barr virus expression in lymphomas from immunocompromised and immunocompetent patients. Am J Pathol (1990) 0.93
Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma. Curr Infect Dis Rep (2003) 0.77
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
The pathology and nomenclature of Hodgkin's disease. Cancer Res (1966) 6.23
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst (1971) 3.30
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol (1994) 3.22
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Granulocytic sarcoma in nonleukemic patients. Cancer (1986) 2.87
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer (2001) 2.59
The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med (1998) 2.57
A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. J Acquir Immune Defic Syndr (1990) 2.57
Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma. J Clin Oncol (1990) 2.46
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Neuroblastomas and neuroendocrine carcinomas of the nasal cavity: a proposed new classification. Cancer (1982) 2.16
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer (2001) 2.08
Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys (1995) 2.05
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 1.95
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med (1999) 1.88
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Complications of cancer immunotherapy with levamisole. Lancet (1977) 1.76
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol (2001) 1.76
Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med (1994) 1.75
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Mantle-cell lymphoma. Lancet Oncol (2001) 1.70
Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion (1999) 1.69
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood (2001) 1.64
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
History of cigarette smoking and risk of leukemia and myeloma: results from the Adventist health study. J Natl Cancer Inst (1990) 1.60
Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol (1994) 1.58
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Enlargement of the supraclavicular lymph nodes as the initial sign of prostatic carcinoma. Cancer (1971) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood (1998) 1.54
Expression of interleukin-6 in Castleman's disease. Hum Pathol (1993) 1.53
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 1.52
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51
Nasopharyngeal lymphoid tissue masses in patients with human immunodeficiency virus-1. Histologic findings and clinical correlation. Cancer (1994) 1.51
Skin involvement in Hodgkin's disease. Cancer (1980) 1.51
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood (1992) 1.48
Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med (1988) 1.48
Primary malignant lymphomas of the breast. Cancer (1977) 1.47
The value of immunophenotyping on paraffin sections in the identification of T-cell rich B-cell large-cell lymphomas: lineage confirmed by JH rearrangement. Am J Surg Pathol (1990) 1.47
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Familial patterns of prostate cancer: a case-control analysis. J Urol (1991) 1.45
Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol (1995) 1.45
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol (1996) 1.42
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
Reactive lymph node hyperplasia with giant follicles. Am J Clin Pathol (1982) 1.40
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood (2000) 1.39
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood (1988) 1.36
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant (2006) 1.35
Testicular cancer associated with employment in agriculture and oil and natural gas extraction. Lancet (1984) 1.35
Causes of death in breast cancer: a clinicopathologic study. Cancer (1980) 1.34
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual males. JAMA (1984) 1.31
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood (1999) 1.30
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29